Key facts
- It has raised $200K; the latest was Angel (individual) ($200K) in Jan 2026.
- Notable investors include MBC BioLabs.
- Mivax Therapeutics has filed 4 Form Ds with the SEC since 2025, most recently Jan 2026 ($108K sold to 21 investors).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Mivax Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mivax Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mivax Therapeutics
Operator of a biotechnology company intended to provide treatments. The company is currently operating in Stealth mode.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 2
- Ownership
- Privately Held (backing)
Mivax Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mivax Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mivax Therapeutics in its N-PORT filings yet. We sweep new filings monthly.